2. UroToday Home
  3. Video Lectures

mCRPC Treatment Videos

mCRPC
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal
October 17, 2019
Details
mCRPC
Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin
September 26, 2019
Details
mCRPC
Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor
September 12, 2019
Details
mCRPC
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
August 2, 2019
Details
mCRPC
Radium-223 in Clinical Practice - Phillip J. Koo
August 2, 2019
Details
mCRPC
Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal
June 11, 2019
Details
mCRPC
Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan
May 31, 2019
Details
mCRPC
The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang
May 12, 2019
Details
mCRPC
Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses
April 23, 2019
Details
mCRPC
Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano
March 27, 2019
Details
mCRPC
The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida
January 31, 2019
Details
mCRPC
Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava
January 28, 2019
Details
mCRPC
An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
October 28, 2018
Details
mCRPC
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
October 11, 2018
Details
mCRPC
Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz
May 8, 2018
Details
mCRPC
Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad
May 3, 2018
Details
mCRPC
UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin
January 6, 2018
Details
mCRPC
Sequencing and Combining CRPC Therapies: What Does the Future Hold? - Charles Ryan
November 10, 2017
Details
mCRPC
Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective
September 18, 2017
Details
mCRPC
Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE
October 9, 2017
Details
mCRPC
STAMPEDE and LATITUDE Trials: Issues to Consider - Thomas Keane
August 1, 2017
Details
mCRPC
A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE
June 21, 2017
Details
mCRPC
Preliminary Data from the PROCEED Registry- Oliver Sartor
June 6, 2017
Details
mCRPC
Should AR-V7 Be Used As A Clnical Test? - Philip Kantoff
April 28, 2017
Details
mCRPC
AR-V7: What We Know, What We Think - Christopher Evans
April 27, 2017
Details
mCRPC
AR-V7 Testing in Clinical Practice: Not Ready for Prime Time - Tomasz Beer
April 27, 2017
Details
mCRPC
Treatment of M1 Disease No Local Treatment - Nicolas Mottet
April 19, 2017
Details
mCRPC
Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke
April 19, 2017
Details
mCRPC
Managing the ‘Start’ and ‘Stop’ of Various Therapies for Treating CRPC Patients - Is Timing Everything?- Karim Fizazi
April 18, 2017
Details
mCRPC
When and What hormonal therapy to use for men with castration-sensitive/naive prostate cancer and isolated biochemical recurrence(M0) after radical treatment - Martin Gleave
April 12, 2017
Details
mCRPC
CRPC M0 and M1: Sequencing and Combination Therapy - Take home message - Ian Davis
April 12, 2017
Details
mCRPC
Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi
January 31, 2017
Details
mCRPC
Management of Chronic Pre-existing or Treatment-emergent Adverse Events of the “other" Systemic Therapies - Michael J. Morris
April 10, 2017
Details
mCRPC
Phil Kantoff on AR-V7: Ready for use in daily clinical decision making
March 14, 2017
Details
mCRPC
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan
February 9, 2017
Details
mCRPC
IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - Charles Ryan
July 28, 2016
Details
mCRPC
Abiraterone in Elderly Chemotherapy-Naive Patients with mCRPC - Charles Ryan
April 28, 2016
Details
mCRPC
Charles Ryan on mCRPC Treatment: Combination Therapy - Clinical Case
April 26, 2016
Details
mCRPC
Charles Ryan on mCRPC Treatment: When to Start Abiraterone?
April 26, 2016
Details
mCRPC
Assessment of Corticosteroid-Associated Adverse Events With Long Term Exposure to Low-Dose Prednisone Given With Abiraterone Acetate to mCRPC Patients - Charles Ryan
January 7, 2016
Details
mCRPC
Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer - Michael Cookson
April 1, 2016
Details
mCRPC
Peter Scardino on A Century of Progress in Urologic Cancers 1915-2015 - MSKCC
September 3, 2015
Details
mCRPC
Charles Ryan on Practical Considerations in the Use of Novel Hormone Agents in the Post-ADT Setting
August 17, 2015
Details
mCRPC
William Lowrance on AUA Guideline: Castration-resistant Prostate Cancer Update
May 19, 2015
Details
mCRPC
Journal Club: Final OS Analysis of COU-AA-302 - Abiraterone in mCRPC without Prior Chemo - Charles Ryan
March 27, 2015
Details
mCRPC
Radiographic Progression-free Survival as a Response Biomarker in mCRPC: COU-AA-302 Results - Charles Ryan
March 7, 2015
Details
mCRPC
Alicia Morgans on Transitions in Treating mCRPC: Abiraterone after Sipuleucel-T
February 21, 2015
Details
mCRPC
Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents - Evan Yu
March 11, 2015
Details
mCRPC
Lower Tumor Burden Patient with Progression after Sipuleucel-T, Treated with Abiraterone Acetate - Charles Ryan
January 16, 2015
Details
mCRPC
Thomas Keane on NCCN Guidelines Update - 2015
December 2, 2014
Details
mCRPC
Final OS Analysis of COU-AA-302 - Study of Abiraterone Acetate in mCRPC without Prior Chemo - Charles Ryan
October 28, 2014
Details
mCRPC
Understanding Antigen Spreading in Immunotherapy
August 6, 2014
Details
mCRPC
Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa
June 27, 2014
Details
mCRPC
The Art and Science of Treating Men with CRPC
June 11, 2014
Details
mCRPC
Final Analysis of Early Access Protocol with AA in mCRPC Patients
June 3, 2014
Details
mCRPC
PSMA Antibody Drug Conjugate in Taxane-treated mCRPC
April 14, 2014
Details
mCRPC
Potential Sequencing of Newer Agents for mCRPC
March 28, 2014
Details
mCRPC
Novel Hormonal Therapies
March 27, 2014
Details
mCRPC
State-of-the-Art Advanced Treatment Landscape
March 20, 2014
Details
mCRPC
Sequencing Therapy in Advanced PCa: Focus on Sip-T
March 16, 2014
Details
mCRPC
Treatment of Progressing mCRPC
March 11, 2014
Details
mCRPC
Oral Androgen Receptor Pathway Agents are Changing PCa+ Treatment
February 24, 2014
Details
mCRPC
Androgen Resistance - The Dream Team Research
February 7, 2014
Details
mCRPC
mCRPC PRO
December 3, 2013
Details
mCRPC
Abiraterone Acetate: Evolving Treatment for Metastatic CRPC
November 23, 2013
Details
mCRPC
PSA Changes as a Surrogate for OS in Men with mCRPC
November 21, 2013
Details
mCRPC
The Changing Role of the Urologist
October 30, 2013
Details
mCRPC
Treatment of mCRPC Pre-chemotherapy
September 14, 2013
Details
mCRPC
Treatment of mCRPC
September 13, 2013
Details